因中心或半侧视网膜静脉阻塞所致黄斑水肿抗VEGF治疗第60个月影像学表现及其与治疗结局的关系
SCORE2研究随访至60个月,评估中心或半侧视网膜静脉阻塞所致黄斑水肿患者抗VEGF治疗后的影像学变化。视网膜内层结构紊乱(DRIL)持续存在,基线时96%、第60个月95%仍存在;视网膜下液少于6%;非灌注区面积变化小。基线影像学变量与视力变化或注射次数无相关性。
要点
- 第60个月时少于6%的患眼存在视网膜下液。
- DRIL是最易持续存在的表现,基线96%、第60个月95%仍存在。
- 基线影像学变量与第60个月视力变化或第12至60个月注射次数无相关性。
核心结论
- 这些分析为初始治疗后多年持续存在的功能缺陷提供了解剖学解释。
- 临床实践模式应考虑使用这些影像学检查来帮助解释许多患眼持续存在的功能缺陷。
- 此外,这8个基线影像学变量通常不应依赖来预测视力或治疗强度。
研究设计与样本
- SCORE2研究参与者随访长达60个月,期间进行视力、注射频率及影像学检查(彩色眼底照相、光学相干断层扫描、超广角荧光素血管造影)。
主要发现
- 第60个月时少于6%的患眼存在视网膜下液。
- DRIL是最可能持续存在的表现,基线时96%患眼存在,第60个月时95%仍存在。
- 超广角荧光素血管造影NETWORC网格中,基线平均非灌注区面积为5.0%(95%CI:3.3%-6.8%),至第60个月变化很小。
- ETDRS网格中,基线平均非灌注区面积为2.3%(95%CI:0.7%-3.9%),至第60个月变化很小。
- 基线时任何影像学变量与至第60个月视力变化或变量治疗时间窗(第12个月至第60个月)后注射次数之间均无相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate imaging findings from SCORE2 participants through 60 months, to describe the degree of resolution or progression of these variables, and to correlate changes in these imaging findings to treatment outcomes such as visual acuity and the number of treatments administered. METHODS: SCORE2 participants were followed for up to 60 months. Visual acuity, injection frequency and imaging tests color fundus photography (CFP), optical coherence tomography (OCT), and ultra-widefield fluorescein angiography [UWFA]) were performed throughout this period. RESULTS: Less than 6% of eyes had subretinal fluid at month 60. Disorganization of the retinal inner layers (DRIL) was the most likely finding to persist, present in 96% of eyes at baseline and unchanged at 95% at month 60. For UWFA, at baseline, there was a mean of 5.0% non-perfusion area (95% CI: 3.3%-6.8%) in the NETWORC grid with little change to month 60. For the Early Treatment Diabetic Retinopathy Study (ETDRS) grid, at baseline, there was a mean of 2.3% non-perfusion area (95% CI: 0.7%-3.9%) with little change to month 60. There was no correlation between any of the imaging variables at baseline and change in visual acuity to month 60 or in the number of injections following the variable treatment timeframe (month 12 to month 60). CONCLUSIONS: These analyses provide an anatomic explanation for persistent functional deficits many years following initial treatment. Clinical practice patterns should consider evaluation with these imaging tests to help explain persistent functional deficits in many eyes. Additionally, these 8 baseline imaging variables generally should not be relied on to predict visual acuity or intensity of treatment. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
引用
- Ip MS, Scott IU, VanVeldhuisen PC, et al. Month 60 Imaging Findings and Relationship to Treatment Outcomes Following Anti-VEGF Therapy for Macular Edema Due to Central or Hemi-Retinal Vein Occlusion. Am J Ophthalmol. 2023. PMID: 38061584. doi:10.1016/j.ajo.2023.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。